Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry”

  • sponsor
    Duke University
Updated on 25 March 2021


Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry”


The primary goal is to address several key treatment and management issues surrounding patients with either AIS or ICH on anticoagulant therapy. In particular, attention will be focused on coagulation tests, utilization of thrombolytic therapy for AIS, treatment patterns and clinical outcomes for AIS and ICH patients on anticoagulant therapy.

Please contact Candida Barlow, Director, St. John Clinical Research Institute
1725 E. 19th St. Suite 701
Tulsa, OK 74104
Office: 918-744-3426 Fax: 918-403-0018

Condition Stroke
Clinical Study IdentifierTX151537
SponsorDuke University
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Patients are eligible to be included in the study if they meet the following criteria
Age 18 years or older
Have been diagnosed with acute ischemic stroke and have been treated with dabigatran, rivaroxaban, apixaban, edoxaban within 7 days prior to admission, or
Have been diagnosed with intracerebral hemorrhage and have been treated with warfarin or one of the new oral anticoagulants within 7 days prior to admission
ARAMIS PRO follow-up study: Ability of patient or legally authorized representative to provide informed consent for longitudinal follow-up indicating they understand the purpose and the requirements of the study and are willing to participate

Exclusion Criteria

Patients who were transferred from another hospital or discharged to other acute care facility will be excluded
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note